NeuPath Health (NPTH) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
14 May, 2026Executive summary
Operates 12 regulated medical facilities in Alberta and Ontario, focusing on MSK and chronic pain, with 150 healthcare professionals and 200,000 annual patient visits.
Achieved record first quarter total revenue of $21.5 million, up 11% year-over-year, driven by increased patient visits and expanded service offerings.
Adjusted EBITDA rose 15% year-over-year to $1.5 million, reflecting operational improvements and higher capacity utilization.
New CEO Stephen Lemieux appointed on April 1, 2026, with a focus on profitability and strategic growth.
Expansion efforts include onboarding new physicians and opening a new location in Guelph, Ontario, expected in late Q3.
Financial highlights
Q1 2026 revenue increased 11% year-over-year to CAD 21.5 million.
Adjusted EBITDA rose 15% to CAD 1.5 million, outpacing revenue growth.
Clinic revenue grew 12% year-over-year, though gross margin declined slightly due to increased staffing and training costs.
Gross margin was $3.96 million (18.4% of revenue), slightly down from 18.8% in Q1 2025.
Cash and cash equivalents stood at $3.5 million, with long-term debt of $6.0 million as of March 31, 2026.
Outlook and guidance
Plans to onboard 6–8 additional physicians in 2026, in addition to 2 already onboarded in Q1.
Continued focus on expanding physician hours, leveraging technology and AI for efficiency.
Active M&A pipeline with mid-to-late stage discussions in BC, Alberta, and Ontario.
Management expects continued operational improvements and execution of growth opportunities throughout 2026.
Q2 is typically the strongest quarter, but prior year included a one-time payment adjustment.
Latest events from NeuPath Health
- Strong revenue growth and expanding physician capacity drive value in a fragmented pain care market.NPTH
2026 Bloom Burton & Co. Healthcare Investor Conference24 Jun 2026 - Q2 2024 revenue up 11% year-over-year, gross margin at 20.0%, net debt down 37%.NPTH
Q2 202428 May 2026 - Q3 2024 revenue and adjusted EBITDA both rose 9% year-over-year, with improved capacity and lower net debt.NPTH
Q3 202428 May 2026 - Revenue and adjusted EBITDA rose year-over-year, with new growth investments and clinical milestones.NPTH
Q4 202428 May 2026 - Record revenue and margin growth in Q1 2025, with new financing and leadership for future expansion.NPTH
Q1 202528 May 2026 - Record revenue and EBITDA growth driven by clinic optimization and new procedure uptake.NPTH
Q2 202528 May 2026 - Strong revenue and EBITDA growth, expanding network, and robust balance sheet position.NPTH
Investor presentation26 Mar 2026 - Record 2025 revenue and EBITDA growth, with strong outlook for further expansion and margin gains.NPTH
Q4 202526 Mar 2026 - Q3 2025 revenue up 26% and adjusted EBITDA nearly doubled, with strong growth and expansion plans.NPTH
Q3 202517 Nov 2025